NexMed, Inc.
(NasdaqCM: NEXM) After Hours:
0.00 N/A (N/A) 10:00PM EST
| Last Trade: | 2.02 |
|---|
| Trade Time: | Sep 3 |
|---|
| Change: | 0.02 (1.00%) |
|---|
| Prev Close: | 2.00 |
|---|
| Open: | 2.04 |
|---|
| Bid: | N/A |
|---|
| Ask: | 2.95 x 1000 |
|---|
| 1y Target Est: | N/A |
|---|
| Day's Range: | 2.00 - 2.05 |
|---|
| 52wk Range: | 1.80 - 12.60 |
|---|
| Volume: | 38,844 |
|---|
| Avg Vol (3m): | 159,523 |
|---|
| Market Cap: | 25.90M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -6.21 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in USD.
- NexMed To Present at the Rodman & Renshaw 12th Annual Healthcare ConferenceBusiness Wire(Wed, Aug 25)
- NexMed Receives Additional Patent Coverage for IsraelBusiness Wire(Mon, Aug 23)
- NEXMED INC Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements and ExhibitsEDGAR Online(Thu, Aug 19)
- NEXMED INC FinancialsEDGAR Online Financials(Tue, Aug 17)
- NexMed, Inc. Q2 2010 Earnings Call Transcriptat Seeking Alpha(Fri, Aug 13)
- NEXMED INC Files SEC form 10-Q, Quarterly ReportEDGAR Online(Thu, Aug 12)
- Q2 2010 NexMed Earnings Release - After Market CloseCCBN(Thu, Aug 12)
- NexMed Announces 2010 Second Quarter Financial Results Conference CallBusiness Wire(Wed, Aug 11)
- Mohamed Hachicha, Ph.D. Joins NexMed, Inc. as Vice President-Research and Development for NexMed, USABusiness Wire(Mon, Jul 26)
- NexMed: NASDAQ panel OKs continued stock listingAP(Wed, Jul 7)
Financial Blogs
- No Financial Blogs available for NEXM at this time.
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 7.72 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
()
: | N/A |
|---|
| Quarterly EPS Est
()
: | N/A |
|---|
| Mean Recommendation*: | N/A |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
NexMed, Inc. engages in designing and developing pharmaceutical products based on its patented NexACT drug delivery technology. The NexACT drug delivery technology is designed to enhance the delivery of an active drug to improve therapeutic outcom...
View More